Thank you for registering with Pulmonary Fibrosis New’s Clinical Trial Registry.
We will inform you of new clinical trials as information becomes available.
In the meantime, feel free to access these other PF-related resources:
Ofev News:
- Ofev Maintains Effectiveness in Advanced IPF Patients, Real-world Study Shows
- Poor Lung Function Before Starting Ofev Seen as Main Reason for Halting Use in UK Real-world Study
- Ofev of Less Benefit to Severe IPF Patients But Those Who Can Stay on Therapy Gain, Study Finds
- Ofev Prevented Lung Cancer Progression in IPF Patient, Case Report Shows
- Ofev, Sildenafil Combo Shows No Added Benefit in IPF Patients with Poor Lung Function, Study Shows
- Esbriet and Ofev Show Significant Benefits in Real-Life Clinical Setting
- Long-term Use of Ofev Safely Slows IPF Progression, New Phase 3 Extension Trial Data Show
IPF News:
- Repeated Lung Cancer Surgery in IPF Patients May Worsen Outcomes
- Online ‘Personal Health’ Campaign Aims to Educate and Empower People with Lung Diseases
- Breathing Easier on the Canadian West Coast
- PF Brain Fog Struggles and Solutions
- Aloperine May Protect Against Pulmonary Fibrosis in Mouse Model, Study Suggests
- Yankees’ Bernie Williams Talks About His Father’s Journey With IPF
- 4 Common Coughing Triggers for Idiopathic Pulmonary Fibrosis
Esbriet News:
- No New Safety Concerns with Esbriet, Results from Long-term PASSPORT Study Show
- Analysis of Phase 3 Trial Data Shows Benefits of Esbriet for More Advanced IPF Patients
- Esbriet and Ofev Show Significant Benefits in Real-Life Clinical Setting
- Esbriet Enables Stable Lung Function Over 2 Years in IPF Patients, Real-World Study Confirms
- Nationwide Study Reveals Esbriet Use Patterns by PF Patients in Sweden
- Lung Tissue Chip Enables Accurate Testing of Potential PF Therapies, Study Reports
- Esbriet Dose Reductions Don’t Affect Its Potential to Manage IPF, Study Shows
CPF News:
- Evel Knievel: Dedicated to Defying Death, Lost To IPF
- PFF Brings Daughters of PF Program Under Its Wings
- CPF Names 2014 Most Important Year for Pulmonary Fibrosis
- FDA Includes CPF Advocates in IPF Workshop
- CPF Organizing a Series of Educational Activities for the 2014 Pulmonary Fibrosis Awareness Month
- PFF and CPF Documentary About Idiopathic Pulmonary Fibrosis to Air on Discovery Channel
- Coalition for Pulmonary Fibrosis Group Leads National Pulmonary Fibrosis Month
IPF Clinical Trial News:
- 4 Factors that Impact Pulmonary Fibrosis Prevention
- Galecto’s Inhaled TD139 a Promising Therapy for IPF, Scottish Study Finds
- Bellerophon’s INOpulse Inhaled Nitrous Oxide Device Improves Symptoms of PH-IPF Patients, Study Finds
- Kadmon Presents Preclinical Data Supporting ROCK Inhibition as Way of Treating PF
- First Patient Enrolled in Trial of Ofev for Progressive Fibrosing Interstitial Lung Disease
- IPF Patients on Esbriet Live Approximately 2.5 Years Longer Than Untreated Patients, Study Finds
- Clinical Trial Shows TD139 as a Promising Therapy Against Pulmonary Fibrosis, Maker Says
FDA News:
- X-Rx Completes Early Studies on X-165 for Potential IPF Treatment, Supporting IND Application
- FDA Puts FibroGen’s Pamrevlumab on Fast Track as IPF Treatment
- US ‘Right to Try’ Law Meets with Mix of Praise and Criticism, Including Among Those with Rare Diseases
- Reviva’s Investigational Therapy RP5063 Receives FDA Orphan Drug Status for IPF Treatment
- Rare Disease Groups Welcome FDA’s Embrace of ‘Real World’ Data in Clinical Trials
- US Lawmakers Urge Bipartisan Support for Rare Disease Research, Patients’ Needs
- Rare Disease Groups, Patients Differ on ‘Right to Try’ Bill Before US Congress